Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study

Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study

Abstract Background The prognosis of patients with small cell lung cancer (SCLC) and brain metastases (BM) was poor. This study aimed to explore the efficacy and safety of anlotinib as third‐line or above treatment in SCLC with BM. Methods This was a subgroup analysis of the ALTER1202 trial, which w...

Full description

Bibliographic Details
Main Authors: Ying Cheng, Qiming Wang, Kai Li, Jianhua Shi, Baohui Han, Lin Wu, Gongyan Chen, Jianxing He, Jie Wang, Haifeng Qin, Xiaoling Li
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Innovation
Subjects:
anlotinib
angiogenesis inhibitors
brain metastasis
advanced small cell lung cancer
safety
Online Access:https://doi.org/10.1002/cai2.43

Internet

https://doi.org/10.1002/cai2.43

Similar Items